Tim Cortese

Niraparib plus dostarlimab with platinum-based chemotherapy achieved superior PFS, meeting the primary end point of the phase 3 FIRST-ENGOT-OV44 trial.

The FDA set a PDUFA date for glofitamab in relapsed or refractory diffuse large B-cell lymphoma for July 20, 2025.

The combination of onvansertib plus FOLFIRI/bevacizumab showed promise among patients with KRAS-mutated metastatic colorectal cancer.

Five-fraction SBRT was noninferior to radiotherapy in a phase 3 trial of patients with low- to intermediate-risk localized prostate cancer.

Anitocabtagene autoleucel may be a promising CAR-T cell therapy option for patients with relapsed/refractory myeloma.

Extended lymphadenectomy did not improve DFS or OS, and led to a higher incidence of perioperative morbidity and mortality.